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Abstract
Background—Standard therapy for stage II/III rectal cancer consists of a fluoropyrimidine and
radiation therapy followed by surgery. Preclinical data demonstrated that bortezomib functions as a
radiosensitizer in colorectal cancer models. The purpose of this study was to determine the maximum
tolerated dose (MTD) of bortezomib in combination with chemotherapy and radiation.
Patients and Methods—Patients with locally advanced rectal adenocarcinomas, as staged by
endoscopic ultrasound, were eligible. Bortezomib was administered on days 1, 4, 8, and 11 every 21
days for 2 cycles with 5-fluorouracil at 225 mg/m2/day continuously and 50.4 Gy of radiation. Dose
escalation of bortezomib was conducted via a standard 3 + 3 dose escalation design. A subset of
patients underwent serial tumor biopsies for correlative studies.
Results—Nine patients in 2 dose cohorts were enrolled. Diarrhea was the principal dose-limiting
toxicity and occurred at the 1.0-mg/m2 dose level. There was no clear evidence of suppression of
nuclear factor-κB target gene expression in biopsy samples.
Conclusion—The MTD of bortezomib in combination with chemotherapy and radiation may be
below a clinically relevant dose, limiting the clinical applicability of this combination. Performing
biopsies before and during irradiation for determining gene expression in response to radiation
therapy is feasible.
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For locally advanced rectal adenocarcinoma, neoadjuvant chemoradiation with 5-fluorouracil
(5-FU) and radiation are widely applied to decrease local recurrence after surgical resection.
1,2 Despite the use of chemoradiation therapy (CRT) and optimal surgery, local recurrence
rates vary from as low as 5% to as high as 25%, depending upon clinical features such as T
(tumor) and N (node) stage as well as distance from the anal canal. Pathologic response to
neoadjuvant chemoradiation therapy assessed at the time of surgical resection has become an
accepted surrogate marker for outcome, with current regimens producing a complete
pathologic response approximately 10%-20% of the time.3 Based on our preclinical data, we
developed a strategy to improve local control and pathologic response rates using continuous
infusion 5-FU CRT plus bortezomib, an agent with interesting biologic properties that might
increase apoptosis as well as provide radiation sensitization.
Bortezomib is a modified dipeptidyl boronic acid derived from leucine and phenylalanine that
acts as an inhibitor of the 26S proteasome, an adenosine triphosphate–dependent multicatalytic
protease. The ubiquitin-proteasome pathway is important for intracellular protein degradation
in eukaryotic cells, and the 26S proteasome plays a vital role in degrading regulatory proteins
that govern the cell cycle, transcription factor activation, apoptosis, and cell trafficking.4
An indirect but important target of the proteasome is transcription factor nuclear factor-κB
(NF-κB), which associates with an inhibitor protein, IκB protein (IκB), in the cell’s cytoplasm.
When the proteasome disposes of ubiquitinated IκB, NF-κB is free to enter the cell’s nucleus,
where it influences the transcription of genes whose proteins encourage survival and
proliferation. Restricting NF-κB’s activity by preventing degradation of IκB sensitizes cells to
chemotherapy and radiation. NF-κB has been shown in colorectal cancer models to be activated
in response to chemotherapy and radiation.5 Specific inhibition of NF-κB activation, either by
proteasome inhibition or by insertion of a nondegradable IκB, leads to increased sensitivity of
tumor cells to radiation therapy.
On this basis, we designed a phase I study to evaluate the safety and maximum tolerated dose
(MTD) of bortezomib when combined with continuous-infusion 5-FU and radiation therapy
in the treatment of patients with locally advanced, recurrent, or metastatic rectal cancer. As a
single agent at its MTD of 1.3 mg/m2 on days 1, 4, 8, and 11 of 21, bortezomib causes diarrhea
in approximately 50% of patients (grade 3 diarrhea, 7%), peripheral neuropathy in about 40%
of patients with myeloma (grade 3 neuropathy, 14%), and thrombocytopenia in about 40%
(grade 3 thrombocytopenia, 27%).6 A dose-escalation study of bortezomib was performed to
determine the MTD of bortezomib when it is administered concurrently with standard-dose
continuous-infusion 5-FU and external-beam radiation. Response was measured by pathologic
evaluation of the surgical specimen. In a subset of patients, we were also able to obtain serial
tumor biopsies to assess the transcriptional levels of mRNAs that are regulated by NF-κB to
determine whether bortezomib at that dose level could functionally repress NF-κB activation.
Patients and Methods
The Institutional Review Boards of the University of North Carolina and Vanderbilt University
approved this clinical trial. Each patient gave written informed consent before enrollment.
Eligibility criteria included patients who had histopathologically confirmed rectal carcinoma,
clinically staged II or III (T3, T4, and/or node-positive disease). Patients with known distant
metastasis who, according to the treating physician, required local therapy for palliative reasons
or in whom potentially curative resection of metastatic disease would be attempted were also
eligible. Patients who developed local recurrence of rectal cancer following surgery alone and
who were felt to require radiation therapy, regardless of clinical stage, were eligible for this
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study. An Eastern Cooperative Oncology Group performance status of 0-2, a life expectancy
> 3 months, and the following laboratory requirements at entry were also required: white blood
cell count ≥ 4000/μL; absolute neutrophil count > 2 × 109/L; platelet count ≥ 100,000/μL;
serum creatinine ≤ 1.5 mg/dL; and total bilirubin ≤ 1.5 mg/dL within 14 days of the start of
therapy.
Pregnant women were excluded, as were patients who had previous pelvic radiation therapy.
Patients with the following conditions were also ineligible: a serious medical or psychiatric
illness that would prevent informed consent or limit survival to < 2 years, a history of refractory
congestive heart failure or cardiomyopathy, active coronary artery disease or a history of
myocardial infarction within 3 months of treatment, or a history of stroke within 3 months of
treatment.
Radiation Therapy
Volumes were planned using computed tomography (CT) conformal planning techniques. The
gross tumor volume (GTV) was defined as the gross tumor as identified by all available clinical
data including CT/magnetic resonance imaging, endoscopic evaluation, and physical
examination. Lymph nodes < 1.5 cm were considered part of the GTV. The clinical target
volume (CTV) was defined as the GTV with a 2-cm margin. In addition, the CTV included the
presacral space with the superior boundary at the sacral promontory and the inferior border
approximately 3-5 cm below the lesion and including the perirectal soft tissue in this range.
The CTV included the entire mesorectal soft tissue, although irradiation to the anal canal was
minimized as much as possible. A margin for set-up error and/or patient motion was added to
the CTV of at least 1 cm. The exact margins were left to the discretion of the treating radiation
oncologist and did not have to be uniform in all dimensions.
The tumor dose was calculated at the isocenter of the multiple fields. The dose was delivered
using megavoltage accelerators with a minimum energy of 10 MV. Patients were treated using
180 cGy per fraction, 1 fraction per day, 5 days per week (excluding holidays), to give a total
of 4500 cGy in 25 fractions to the large pelvic field. Attempts were made to minimize the
amount of small bowel in the radiation field and to minimize irradiation of anus, perianal skin,
and bladder if this could be done without compromising treatment of the tumor volume.
Treatments were given with either a 3-field (posterior-anterior [PA] and laterals) or a 4-field
(anterior-posterior [AP]/PA and laterals) technique. An additional 540 cGy, 180 cGy per day,
5 days per week was delivered for an additional 3 fractions to the gross tumor volume while
minimizing dose to small bowel in this field. This was generally delivered with paired lateral
fields or 3-field techniques (PA and laterals).
Drug Therapy
Doses of 5-FU and bortezomib for planned cohorts are shown in Table 1 and the treatment
schema in Figure 1. On day 1, radiation was administered within 3 hours of the bortezomib
administration. Bortezomib was given biweekly for 5.5 weeks on weeks 1, 2, 4, and 5 on
Monday and Thursday or on Tuesday and Friday. Continuous infusion of 5-FU via ambulatory
pump at 225 mg/m2 was begun on day 2 (to allow for serial tumor biopsy collection for NF-
κB target gene analysis in patients who consented to serial biopsies) and continued until
radiation was completed.
Patients received weekly physical examinations, blood counts, chemistries, tests of liver
function, and urinalysis. Toxicity was assessed according to National Cancer Institute Common
Toxicity Criteria, version 2.0. No dose modifications were made for radiation therapy toxicity;
if radiation therapy was held, then 5-FU and bortezomib would likewise be held until the
toxicity subsided. 5-Fluorouracil was interrupted for 1 week and dose reduced 20% for grade
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3 diarrhea or grade 2 diarrhea not controlled by medication, palmar-plantar erthrodysesthesia,
stomatitis, or hematologic toxicity. A second dose reduction of 20% followed the first dose
reduction if toxicity recurred. If bortezomib was interrupted because of a grade 4 hematologic
or grade ≥ 3 nonhematologic toxicity, the same dose was continued if the toxicity resolved
after only 1 dose was missed. If 2 doses were missed (either consecutive or out of cycle) then
bortezomib dosing was reduced as follows: 1.3- or 1.5-mg/m2 cohorts had bortezomib reduced
to 1.0 mg/m2; and the 1.0-mg/m2 cohort was reduced to 0.70 mg/m2. If the dose was 0.70 mg/
m2, then bortezomib was discontinued.
Dose-limiting toxicity (DLT) was defined as any grade ≥ 3 nonhematologic toxicity or grade
4 hematologic toxicity that did not resolve to grade ≤ 2 within 1 week and thereby led to more
than a week’s delay in treatment. Grade 3 nausea or vomiting was not considered a DLT unless
patients did not respond to appropriate changes in the antiemetic regimen in a subsequent cycle.
The MTD was defined as the maximum dose of bortezomib associated with DLT occurring in
less than one third of the patients treated in a particular dose cohort.
Surgical Resection
Timing of surgical therapy was not mandated by the protocol, but generally occurred 4-8 weeks
after radiation therapy was completed. Evaluation of pathologic response at the time of surgical
resection was classified according to the tumor-node-metastasis (TNM) staging system of the
American Joint Committee on Cancer/International Union Against Cancer using the prescript
“y” (ie, yp). Histologically viable tumor was used to assess the pathologic stage. Pathologic
complete response (pCR) was defined as the complete absence of viable tumor cells in the
resected specimen. A major pathologic response was defined as the presence only of
microscopic residual tumor in the resection specimen (measuring < 1 mm). Any specimen with
gross disease was classified as a pathologic poor responder.
Tumor Biopsies and Correlative Studies
Biopsies were performed in the subset of patients who consented at 3 time-points: before the
initiation of radiation therapy, 2-6 hours after first radiation therapy fraction and 24 hours after
the first radiation therapy fraction. Four to six biopsies were taken by rigid sigmoidoscopy at
each interval. Half of the biopsies were frozen for RNA extraction, and half were fixed in
formalin.
Quantitative Fluorescence Reverse Transcriptase Polymerase Chain Reaction
Total RNA was isolated from frozen biopsy samples using an RNeasy kit (Qiagen; Valencia,
CA). DNA contamination was resolved by treating all RNA isolates with DNase I RNase free
(Ambion; Foster City, CA). Samples were diluted to 2 ng/μL, and 5 μL/reaction was used.
Samples were run in triplicate.
Applied Biosystem’s Primer Express software was used to design primers for the following
genes: BCL2, Bcl-xL, cIAP1, cIAP2, TRAF1, TRAF2, IκBα, IKKε, IL-8, and cyclin D1. Probes
were labeled with 5′FAM-3′BHQ-1. One-step reverse transcriptase polymerase chain reaction
was performed (40 cycles). Values for relative mRNA expression were derived by calculating
the mean cycle number, normalizing by subtracting 40 from the mean (40 = the maximum
number of cycles) then calculating en where n is the normalized cycle number value.
Statistical Methods
Overall survival was defined as the time from the date of first treatment to the date of death or
last contact. The Kaplan-Meier method was used to estimate median overall survival. Statistical
analyses were performed using SAS statistical software, version 9.2 (SAS Institute Inc.; Cary
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NC). This study was approved by the University of North Carolina at Chapel Hill Committee
on the Protection of the Rights of Human Subjects.
Results
Ten patients were enrolled onto the study between November 2003 and August 2008;
demographic and disease-related information are shown in Table 2.
Toxicity
Patients were initially treated with bortezomib at 0.7 mg/m2, with escalations and reductions
as show in Table 3. One patient at dose level 1 (DL1) discontinued treatment after 4 weeks
because of atypical chest pain and shortness of breath, which was diagnosed as
gastroesophageal reflux disease and resolved after a day. The patient withdrew after this of her
own accord and was replaced as the toxicity did not meet criteria for DLT. Nine patients
completed therapy, with grade 3 and 4 adverse events as shown in Table 4. Doses of bortezomib
were not increased above 1.0 mg/m2 because of grade 3 diarrhea, the most frequently occurring
toxicity. In DL2 grade 3 diarrhea was observed in 2 out of 3 patients and resolved by 6 days
in both patients. One of these patients also had grade 3 hypoalbuminemia and hypokalemia
and was subsequently hospitalized for an ileus, which resolved in 2 days. His therapy was held
and bortezomib and 5-FU doses were reduced when therapy recommenced. The second of the
patients at DL2 with diarrhea also had dose reductions in bortezomib and 5-FU. Because of
this toxicity, the DL1 cohort was expanded by 3 patients to a total of 6; one of the new patients
at DL1 had diarrhea that lasted 3 days, prompting dose modification of 5-FU. There was no
grade 3 or 4 neuropathy or hematologic toxicity observed in the trial. The MTD of bortezomib
in combination with 5-FU and radiation therapy was determined to be 0.7 mg/m2 day.
Pathologic Response to Therapy and Survival
Of the 9 patients who completed the trial, all 9 underwent resection. Microscopic evaluation
of the specimens showed that 1 patient had a pCR, 1 had microscopic residual disease, and 7
had gross residual disease. Clinical staging before surgery was compared with pathologic
staging (Table 5). At the time of analysis, 5 patients had no evidence of disease, 1 was alive
with disease, and 3 were deceased, having died of the disease at 3 months, 6 months, and 26
months. Three patients were alive more than 2 years out (at 25 months, 25 months, and 29
months). The median follow-up for survivors was approximately 13 months (range, 1-29
months). The median survival time for this cohort of patients was almost 26 months.
Nuclear Factor-κB Target Gene Expression
Baseline and 24-hour (after bortezomib) biopsy pairs from 5 patients were evaluable for NF-
κB target gene expression by reverse transcriptase polymerase chain reaction. Two patients
(patients 2 and 5) also had biopsies at an early timepoint (2-4 hours post radiation therapy).
Results are shown in Figure 2. Interestingly, the only patient who underwent biopsy and who
also achieved a complete pathologic remission at the time of surgery had a marked increase in
NF-κB target gene mRNA copy number at 24 hours compared with baseline, suggesting that
NF-κB was not being inhibited by bortezomib (at 1.0 mg/m2). This patient experienced a DLT
of diarrhea and then had recurrence of grade 3 diarrhea during postoperative 5-FU/leucovorin
administration, suggesting sensitivity to 5-FU; he remains disease free at 4 years. For the poor
responders (gross residual disease present), the general trend was for a decrease in NF-κB target
gene expression, with the exception of one patient who had a substantial increase in TRAF1
expression at 24 hours. These results would seem to indicate that some degree of repression
of NF-κB–related gene expression did occur at the 2 dose levels tested but that this repression
did not necessarily result in better clinical response. Statistical analysis was not performed
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because of the small numbers of patients assayed, and as such, our conclusions are limited in
this regard.
Discussion
Preclinical data suggested a strong biologic rationale to study the use of bortezomib in
combination with radiation therapy in the treatment of rectal cancer. NF-κB activation by
radiation contributes to radioresistance in vitro and in vivo, and inhibition of NF-κB can
sensitize colorectal tumors in model systems.5 Similarly, in a radioresistant breast cancer
model, gene array experiments performed to identify expression changes associated with the
development of radioresistance demonstrated increased expression of NF-κB–regulated genes
in radioresistant cells compared with parental radiosensitive cells.7 Furthermore, baseline NF-
κB activation as measured by immunohistochemistry has been correlated with response to
chemoradiation in esophageal cancer8 and with response to chemotherapy plus cetuximab in
patients with colorectal cancer.9 This study is the first to attempt to demonstrate the feasibility
of combining bortezomib with 5-FU and radiation in patients with advanced rectal cancer. The
major toxicity was diarrhea, which limited the MTD to 0.7 mg/m2, the first dose level evaluated
in this study. By comparison, in a phase I trial combining bortezomib and 5-FU, the
recommended dose of bortezomib was 0.7 mg/m2 twice weekly for 4 weeks administered with
bolus 5-FU for 4 out of 6 weeks. Neuropathy was not encountered at this dose, but diarrhea
was prominent.10 Similarly, a phase I trial conducted in patients with head and neck cancer
reached a dose of only 0.6 mg/m2 twice weekly with DLTs including dehydration and
hyponatremia.11 In terms of outcome, 1 pCR out of 10 evaluable patients is in line with the
8% pCR rate with 5-FU–based CRT in the study by Sauer et al12 but not indicative of additivity
or synergy between bortezomib at the doses given and the other components of therapy.
In primates the target level of proteasome inhibition should not exceed 80%, which would
occur at a dose of 1.96 mg/m2. A dose of 1.3 mg/m2 is sufficient to inhibit 60% of proteasome
activity.13 It has been shown that proteasome inhibition is dose dependent.14,15 Incomplete
inhibition of the proteasome by bortezomib or use of alternative pathways which allow survival
might in part explain the apparent relative resistance of epithelial malignancies to bortezomib.
16 We reached a dose of only 0.7 mg/m2 twice weekly in our study and did not proceed to
phase II evaluation because of concerns that the dose would not be biologically meaningful.
Additionally, only 1 of 9 patients experienced a pCR at the MTD, suggesting that this is not
an active regimen.
Conclusion
Although our study was unable to reach a biologically meaningful dose, it demonstrated the
feasibility of evaluating the response of a target gene to therapy through serial tumor biopsy.
Although biopsies were mandatory in the initial study design, we subsequently made them
optional to help increase study participation. In the samples obtained, we were able to purify
high-quality RNA for polymerase chain reaction–based studies to evaluate the NF-κB response
to bortezomib. Given our small numbers of biopsy samples, we were not able to draw strong
conclusions about the effect of bortezomib on NF-κB–dependent gene expression.
Parenthetically, the patient with the best response (and significant gastrointestinal toxicity) had
tremendous increases in several NF-κB–dependent genes on tumor biopsy at 24 hours after
bortezomib administration and radiation; this observation runs counter to our initial hypothesis
that increases in NF-κB suppress apoptosis and contribute to radioresistance. It is possible that
upreglation of NF-kB–dependent genes is an attempt by the cell to overcome the proapoptotic
stimulus of radiation therapy; or that the NF-κB response is proapoptotic rather than
antiapoptotic as is generally believed. We have also examined the relationship between NF-
κB expression and response to radiation therapy in patients treated with standard 5-FU–based
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chemoradiation and have found that, in general, NF-κB induced genes are upregulated by
radiation but that baseline NF-κB status does not correlate with pathologic response to radiation
therapy (O’Neil, B; manuscript in preparation), further tempering our enthusiasm for pursuing
this particular drug-radiation combination.
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Figure 1. Treatment Schema
aBortezomib is given during weeks 1, 2, 4, and 5 on a Monday/Thursday or Tuesday/Friday
schedule.
bRadiation should be administered within 3 hours following bortezomib administration.
c5-FU continuous infusion by ambulatory pump of choice throughout radiation treatment.
dDuring the first week only 5-FU will be started on day 2 of radiation therapy to allow for
biopsies for biologic endpoints in the presence of radiation therapy and bortezomib alone.
Abbreviation: 5-FU = 5-fluorouracil
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Figure 2. Quantitative Fluorescence Reverse Transcriptase Polymerase Chain Reaction Was
Performed Across 5 Patients for 6 Representative Genes That Are Known Target Genes of
Activated NF-κB
Results for 6 representative genes are shown here. T0 refers to pretreatment baseline and is
compared with the early timepoint (T2-6) and 24-hour timepoint (T24) for each patient. Patients
were ordered by pathologic response from gross residual disease (GR) to microscopic residual
(MR) to complete response (CR). Patients 2 and 5 in the figure had early timepoints analyzed
as well (2-4 hours after radiation therapy). The results indicate lack of suppression of NF-κB
target gene transcription.
Abbreviations: NF-κB = nuclear factor-κB; pCR = pathologic complete response
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Cohort Minus 1 0.70 mg/m2 185 mg/m2 180 cGy
Cohort 1 0.70 mg/m2 225 mg/m2 180 cGy
Cohort 2 1.0 mg/m2 225 mg/m2 180 cGy
Cohort 3 1.3 mg/m2 225 mg/m2 180 cGy
Cohort 4 1.5 mg/m2 225 mg/m2 180 cGy
Abbreviation: 5-FU = 5-fluorouracil
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Table 2














Abbreviation: ECOG = Eastern Cooperative Oncology Group













O’Neil et al. Page 13
Table 3









0.7 3 0 –
1.0 3 2 20% 5-FUand bortezomib
0.7 3 1 20% 5-FU
Abbreviations: 5-FU = 5-fluorouracil; DLT = dose-limiting toxicity
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Table 4
Grade 3/4 Adverse Events by Dose Level
Adverse Event
Bortezomib Dose
0.7 mg/m2 (n = 6) 1.0 mg/m2 (n = 3)







n = number of patients evaluable for toxicity.
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Table 5







1 T3 Nx M1 ND Gross residual
2 T3 N1 M0-R T2 N0 MX Gross residual (0.3 cm)
3 T3 N1 M0 T2 N0 MX Gross residual
4 T3 N0 M0 T3 N0 MX Gross residual
5 T3 N1 M0 T0 N0 CR
7 ND-R T4 N0 M0 Gross residual
8 T3 N1 M0 T3 N1 M0 Microscopic residual
9 T3 N1 M0 T2 N1 MX Gross residual
10 T3 N1 M0 T3 N1 MX Gross residual
11 T3 Nx M0 T2 N0 Microscopic residual
Patient 6 was consented but not treated.
Abbreviations: CR = complete response; ND = not determined (patient initially had T2 N0 disease but at recurrence had bulky disease by computed
tomography, so endoscopic ultrasound not felt necessary to recommend chemoradiation and exception was allowed); R = recurrence
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